Michael Henderson, Chief Executive Officer at Apogee Therapeutics, shared on LinkedIn:
“Today, Apogee Therapeutics officially becomes part of AbbVie. I couldn’t be prouder of what our team built, and am grateful for AbbVie’s partnership and belief in our mission to serve patients with immunological and inflammatory diseases.
Thank you to all the patients and investigators that have been part of this effort from the beginning, without which nothing would be possible, in addition to the team, board, and investors for getting us here. Excited for this next chapter with AbbVie.”
Other articles about AbbVie on OncoDaily.